Information Provided By:
Fly News Breaks for August 12, 2019
AMGN
Aug 12, 2019 | 08:00 EDT
Wells Fargo analyst Jim Birchenough raised his price target for Amgen to $202 from $197 following the positive District Court decision on ENBREL patents. With validity of ENBREL patents affirmed, the analyst also adjusted his sales estimates to reflect stable trends, and lack of biosimilar erosion beyond 2019. Nonetheless, Birchenough reiterates a Market Perform rating on the shares as he believes the stock is fully-valued relative to growth, even with upward revision to ENBREL estimates.
News For AMGN From the Last 2 Days
There are no results for your query AMGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.